Jazz Pharmaceuticals (JAZZ) Other Non-Current Liabilities (2012 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Other Non-Current Liabilities of $161.5 million for Q1 2026, up 77.24% year-over-year from $91.1 million in Q1 2025, and up 29.82% quarter-over-quarter from $124.4 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $161.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 77.24% year-over-year to $161.5 million; the TTM figure through Mar 2026 stood at $161.5 million (up 77.24% YoY), while the FY2025 annual figure was $124.4 million, up 43.63% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $161.5 million, up from $124.4 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $161.5 million in Q1 2026, with the low at $86.6 million in Q4 2024.
- The 5-year median for Other Non-Current Liabilities is $122.7 million (2023), against an average of $116.6 million.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities decreased 29.41% in 2024, then surged 77.24% in 2026.
- Jazz Pharmaceuticals' Other Non-Current Liabilities stood at $144.0 million in 2022, then dropped by 14.78% to $122.7 million in 2023, then retreated by 29.41% to $86.6 million in 2024, then surged by 43.63% to $124.4 million in 2025, then grew by 29.82% to $161.5 million in 2026.
- Business Quant data shows JAZZ's Other Non-Current Liabilities at $161.5 million in Q1 2026, $124.4 million in Q4 2025, and $108.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140.90 Mn |
| Mar 31, 2026 | 161.50 Mn |
| Dec 31, 2025 | 124.40 Mn |
| Sep 30, 2025 | 108.91 Mn |
| Jun 30, 2025 | 93.73 Mn |
| Mar 31, 2025 | 91.12 Mn |
| Dec 31, 2024 | 86.61 Mn |
| Sep 30, 2024 | 110.97 Mn |
| Jun 30, 2024 | 99.42 Mn |
| Mar 31, 2024 | 97.43 Mn |
| Dec 31, 2023 | 122.69 Mn |
| Sep 30, 2023 | 127.48 Mn |
| Jun 30, 2023 | 126.68 Mn |
| Mar 31, 2023 | 109.18 Mn |
| Dec 31, 2022 | 143.98 Mn |
| Sep 30, 2022 | 123.94 Mn |
| Jun 30, 2022 | 129.42 Mn |
| Mar 31, 2022 | 124.64 Mn |
| Dec 31, 2021 | 137.87 Mn |
| Sep 30, 2021 | 137.81 Mn |